These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Iodine-123-iodo-lisuride SPECT in Parkinson's disease. Cordes M; Hierholzer J; Schelosky L; Schrag A; Richter WS; Eichstädt H; Schulze PE; Poewe W; Felix R J Nucl Med; 1996 Jan; 37(1):22-5. PubMed ID: 8543995 [TBL] [Abstract][Full Text] [Related]
4. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429 [TBL] [Abstract][Full Text] [Related]
5. Dopaminergic D2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. Chiron C; Bulteau C; Loc'h C; Raynaud C; Garreau B; Syrota A; Mazière B J Nucl Med; 1993 Oct; 34(10):1717-21. PubMed ID: 8410289 [TBL] [Abstract][Full Text] [Related]
6. 2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration? Müller T; Eising EG; Reiners C; Przuntek H; Jacob M; Kuhn W Nucl Med Commun; 1997 Dec; 18(12):1115-21. PubMed ID: 9481757 [TBL] [Abstract][Full Text] [Related]
7. Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET. Baulieu JL; Ribeiro MJ; Levilion-Prunier C; Tranquart F; Chartier JR; Guilloteau D; Cottier JP; Besnard JC; Pourcelot L; Autret A Nucl Med Commun; 1999 Jan; 20(1):77-84. PubMed ID: 9949416 [TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508 [TBL] [Abstract][Full Text] [Related]
13. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. Baron JC; Mazière B; Loc'h C; Cambon H; Sgouropoulos P; Bonnet AM; Agid Y J Cereb Blood Flow Metab; 1986 Apr; 6(2):131-6. PubMed ID: 3485639 [TBL] [Abstract][Full Text] [Related]
14. Iodolisuride and iodobenzamide, two ligands for SPECT exploration of the dopaminergic D2 receptors: a comparative study. Pellevoisin C; Guilloteau D; Baulieu JL; Loc'h C; Dognon AM; Mauclaire L; Saccavini JC; Besnard JC; Chalon S Synapse; 1996 Sep; 24(1):79-86. PubMed ID: 9046079 [TBL] [Abstract][Full Text] [Related]
15. Steele-Richardson-Olszewski-syndrome: reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: (123)IBZM SPECT and MRI study. Arnold G; Tatsch K; Kraft E; Oertel WH; Schwarz J Mov Disord; 2002 May; 17(3):557-62. PubMed ID: 12112207 [TBL] [Abstract][Full Text] [Related]
16. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409 [TBL] [Abstract][Full Text] [Related]
17. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675 [TBL] [Abstract][Full Text] [Related]